Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
Historik

Vælg chat via ovenstående menu
Luk reklame

      
11/5 16:09
af bibob
Mr Winkel. Can you tell us the % of royalty you get from Teprutumumab. ?
11/5 16:09
af Jan Van de Winkel
future milestones could be triggered by clinical progress in daratumumab development as well as sales milestones.
11/5 16:09
af Jan Van de Winkel
The first milestone has just been achieved with the approval of daratumumab in Europe in second line MM (48 mn USD)....approx. 325 mn DKK...
11/5 16:08
af Helge Larsen/PI-redaktør
Bikube: “800 million are expected in milestones. What events trigger these”?
11/5 16:07
af Jan Van de Winkel
the most significant tier, is that when sales exceed 3 bn USD, the royalty rate to Genmab will be 20%.
11/5 16:07
af Jan Van de Winkel
Current royalty is at 12 percent royalty tranche and we expect to step up one tier this year....
11/5 16:06
af kkjoel
Reg. dara royalty-levels: will you down the line, as the various thresholds are exceeded, inform the marked THAT they were exceeded and HOW MUCH the next royalty-%-step is? Or are we for ever destined to guess (which probably WILL come v close to facts).. based on JnJ turnover, approximate dollar-exchange rates, and GENs royalty-income?
11/5 16:05
af Jan Van de Winkel
Expenses 1 bn DKK leading to operating Income of 1 bn DKK, cash greater than 4.5 bn DKK.
11/5 16:05
af Jan Van de Winkel
Revenue guidance for 2017 is around 2 bn DKK....
11/5 16:04
af Helge Larsen/PI-redaktør
Can you tell us about your guiding for 2017?
11/5 16:04
af Jan Van de Winkel
and approval in important second line MM in Europe, and 48 mn USD milestone.
11/5 16:03
af Jan Van de Winkel
Exciting new trials BMS Opdivo, Tecentriq NSCLC, RRMM Dara + POM + d (Apollo), and the start of the Amgen RRMM Dara plus Krypolis + d....
11/5 16:02
af Jan Van de Winkel
up 28 percent to Q4 2016. Launched in 18 EU countries and US...
11/5 16:02
af Jan Van de Winkel
DARZALEX Janssen net sales 255 mn USD....
11/5 16:01
af Jan Van de Winkel
cash position 4.8 bn DKK....a great start to the year. Important events ...
11/5 16:01
af Jan Van de Winkel
revenue growth exceeded expense increase equaling an increase in operating income of 30 mn DKK to 46 mn DKK for Q1....
11/5 16:00
af Jan Van de Winkel
expenses up 33 percent, driven by the investment in our pipeline of products....
11/5 16:00
af Jan Van de Winkel
Revenues up 48 percent driven by DARZALEX royalty income....
11/5 16:00
af Jan Van de Winkel
David will start with the financials....
11/5 16:00
af Helge Larsen/PI-redaktør
Great. First of all let me just congratulate on the great results for Q1 . Can you give us a short-term update on key figures and important events in Q1?
11/5 15:59
af Jan Van de Winkel
We are eager to go!
11/5 15:59
af Helge Larsen/PI-redaktør
Jan van de Winkel and David Eatwell. Welcome to Q & A here on ProInvestor.com. We are very happy to have you back here and ready to answer questions from our investors.
11/5 15:58
af Helge Larsen/PI-redaktør
:-)
11/5 15:57
af Jan Van de Winkel
yes, we are here. Nice to talk to you.
11/5 15:56
af Helge Larsen/PI-redaktør
Jan and David. Are you online?
Nyeste Først- Ældste Først   Side 2/2